Menu
Search
|

Menu

Close
X

Vital Therapies Inc VTL.OQ (NASDAQ Stock Exchange Global Select Market)

0.21 USD
-0.00 (-1.03%)
As of Feb 22
chart
Previous Close 0.21
Open 0.20
Volume 74,943
3m Avg Volume 293,758
Today’s High 0.21
Today’s Low 0.20
52 Week High 9.70
52 Week Low 0.15
Shares Outstanding (mil) 42.21
Market Capitalization (mil) 249.02
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-0.921
FY17
-1.321
FY16
-1.304
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.70
Price to Sales (TTM)
vs sector
--
6.29
Price to Book (MRQ)
vs sector
3.40
5.26
Price to Cash Flow (TTM)
vs sector
--
24.98
Total Debt to Equity (MRQ)
vs sector
0.00
16.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.38
Return on Investment (TTM)
vs sector
-63.60
14.45
Return on Equity (TTM)
vs sector
-63.63
15.96

EXECUTIVE LEADERSHIP

Faheem Hasnain
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Duane Nash
Chief Executive Officer, Director, Since 2019
Salary: $350,000.00
Bonus: --
Michael Swanson
Chief Financial Officer, Since 2013
Salary: $94,791.00
Bonus: $20,854.00
Robert Ashley
Executive Vice President, Chief Technical Officer, Since 2013
Salary: --
Bonus: --
Aron Stern
Chief Administrative Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

15222 Avenue of Science Ste B
SAN DIEGO   CA   92128-3422

Phone: +1858.6736840

Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company's ELAD System consists of approximately four disposable ELAD C3A cell cartridges.

SPONSORED STORIES